Propantheline

Evidence Level: L3

Predicted Indications: 1

Propantheline

Pharmacist Assessment Report

Propantheline: From Peptic Ulcer Disease to Irritable Bowel Syndrome

One-Sentence Summary

Propantheline is an antimuscarinic medicine whose use in peptic ulcer disease is recorded in the knowledge graph. The TxGNN model predicts it may be useful for irritable bowel syndrome (IBS). The data compiled for this report include 3 publications (one randomised trial from 1989, one multicentre combination study and one animal study) and no registered clinical trials.

Quick Overview

Item	Content
Original Indication	Peptic ulcer disease (relation recorded in the knowledge graph; the Australian licence record contains no indication text)
Predicted New Indication	Irritable bowel syndrome
TxGNN Prediction Score	0.9916
Evidence Level	L3
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data are not available in the data compiled for this report. Propantheline is a quaternary ammonium antimuscarinic agent. Drugs of this class block muscarinic receptors (notably M3) on gastrointestinal smooth muscle and secretory cells. This is inferred from the drug class rather than from supplied MOA data.

Blocking these receptors reduces gut motility, spasm and visceral cramping. That fits symptom control in IBS, particularly pain-predominant and diarrhoea-predominant presentations. Peptic ulcer disease and IBS are both gastrointestinal conditions in which reducing smooth-muscle activity and secretion may help.

The high TxGNN score is a computational prediction. It supports prioritisation but is not clinical evidence. The benefit-risk balance is limited by anticholinergic adverse effects (dry mouth, constipation, urinary retention, tachycardia). This matters especially in constipation-predominant IBS and in older patients.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
2697886	1989	RCT	The Quarterly Journal of Medicine	Long-term IBS management in 28 patients who had recovered after 4–6 weeks of ispaghula husk plus propantheline. Patients were randomised to placebo (Group A) or continued treatment (Group B), and relapse was assessed at six months. The abstract supplied is truncated, so the results are not available here.
2888056	1987	Multicentre clinical study (combination)	Minerva Dietologica e Gastroenterologica	Effectiveness and tolerance of a bromazepam plus propantheline combination in IBS patients. No abstract was supplied.
11488427	2001	Preclinical (animal)	Japanese Journal of Pharmacology	Studied YM905, a different M3 antagonist, in rat models of IBS-like bowel dysfunction. It reduced stress-induced fecal output and diarrhoea, which supports the mechanism but does not study propantheline itself.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 13927B	Pro-Banthine	Tablet containing propantheline bromide 15 mg	Not stated in the licence record

Safety Considerations

Knowledge-graph contraindication relations (not label text): The knowledge graph records contraindication relations with many conditions, including:
- Gastrointestinal: intestinal obstruction, paralytic ileus, toxic megacolon, ulcerative colitis and inflammatory bowel disease, achalasia, pyloric stenosis and hiatus hernia.
- Eye, nerve and muscle: angle-closure glaucoma and myasthenia gravis.
- Urinary and prostate: benign prostatic hyperplasia and bladder neck obstruction.
- Cardiovascular and endocrine: coronary artery disease, hypertension and hyperthyroidism.
- Organ disease: kidney, liver and gallbladder disease.
Drug interactions: 100 interactions were identified. The 20 listed in the data compiled for this report are mostly Moderate, with a few Minor. Many involve additive anticholinergic or sedative effects. Examples:
- Other anticholinergics: hyoscyamine, homatropine and aclidinium.
- Antihistamines and amantadine: chlorpheniramine, acrivastine, phenyltoloxamine and amantadine.
- Amitriptyline.
- Opioids: fentanyl, alfentanil, codeine, dihydrocodeine, tramadol and loperamide.
- Alcohol and botulinum toxin type A.
- Minor: acetaminophen and hydrochlorothiazide.

Please refer to the TGA-approved Product Information (PI) for label warnings and contraindications, as these were not available for this report.

Conclusion and Next Steps

Decision: Hold

Rationale:

The only randomised trial is old (1989), tests propantheline together with ispaghula husk, and has no usable results in the data supplied. The other human study is a combination with bromazepam.
No registered trials exist, and label safety data and MOA data are missing. The anticholinergic burden and interaction load further limit the benefit-risk balance.
Evidence is rated L3 because the publications study IBS directly, but the evidence is weak and mostly confounded by combination therapy.

To proceed, the following is needed:

Full text and results of the 1989 randomised trial and the 1987 combination study.
The TGA Product Information (warnings, contraindications and approved indication).
Mechanism of action data for propantheline.
A review of more recent IBS trials of antimuscarinic or antispasmodic agents.
A risk assessment for older patients and for constipation-predominant IBS.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.